• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SVP, Controller & CAO Rutledge Napoleon B Jr sold $283,476 worth of shares (329 units at $861.63), decreasing direct ownership by 50% to 328 units (SEC Form 4)

    11/10/25 2:45:11 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care
    Get the next $MCK alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Rutledge Napoleon B JR

    (Last) (First) (Middle)
    6555 NORTH STATE HWY 161

    (Street)
    IRVING TX 75039

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    MCKESSON CORP [ MCK ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    SVP, Controller & CAO
    3. Date of Earliest Transaction (Month/Day/Year)
    11/07/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/07/2025 S 329(1) D $861.63 328 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Sale pursuant to a previously adopted plan dated February 7, 2025, in compliance with Rule 10b5-1(c).
    /s/ Sarah Ahmad Ali, Attorney-in-fact 11/10/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MCK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MCK

    DatePrice TargetRatingAnalyst
    12/9/2025$960.00Overweight
    Barclays
    12/4/2024$630.00Neutral
    Mizuho
    11/7/2024$531.00 → $688.00Neutral → Outperform
    Robert W. Baird
    9/24/2024$603.00 → $531.00Outperform → Neutral
    Robert W. Baird
    9/5/2024$670.00 → $665.00Outperform
    Leerink Partners
    8/8/2024$540.00 → $570.00Neutral
    Mizuho
    2/26/2024$600.00Outperform
    Leerink Partners
    1/3/2024$537.00Overweight
    Barclays
    More analyst ratings

    $MCK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and Chief Legal Officer Lau Michele sold $2,697,750 worth of shares (2,725 units at $990.00), decreasing direct ownership by 46% to 3,247 units (SEC Form 4)

    4 - MCKESSON CORP (0000927653) (Issuer)

    3/4/26 12:41:44 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    Director Martinez Maria sold $328,013 worth of shares (349 units at $939.87), decreasing direct ownership by 54% to 301 units (SEC Form 4)

    4 - MCKESSON CORP (0000927653) (Issuer)

    2/23/26 1:13:41 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    EVP & Chief HR Officer Smith Leann B sold $179,550 worth of shares (190 units at $945.00), decreasing direct ownership by 6% to 2,989 units (SEC Form 4)

    4 - MCKESSON CORP (0000927653) (Issuer)

    2/18/26 7:04:55 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    SEC Filings

    View All

    McKesson Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MCKESSON CORP (0000927653) (Filer)

    3/6/26 8:04:16 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - MCKESSON CORP (0000927653) (Filer)

    3/5/26 8:16:51 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    SEC Form 10-Q filed by McKesson Corporation

    10-Q - MCKESSON CORP (0000927653) (Filer)

    2/4/26 5:30:50 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on McKesson with a new price target

    Barclays initiated coverage of McKesson with a rating of Overweight and set a new price target of $960.00

    12/9/25 8:51:34 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    Mizuho resumed coverage on McKesson with a new price target

    Mizuho resumed coverage of McKesson with a rating of Neutral and set a new price target of $630.00

    12/4/24 7:43:38 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded McKesson from Neutral to Outperform and set a new price target of $688.00 from $531.00 previously

    11/7/24 6:29:13 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    McKesson Corporation Announces Fourth Quarter Fiscal 2026 Earnings Release Date and Participation in Upcoming Conferences

    McKesson Corporation (NYSE:MCK) will release its fourth quarter fiscal 2026 financial results after market close on Thursday, May 7, 2026. Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. Mr. Vitalone will be participating in Leerink Partners Global Healthcare Conference and Barclays Global Healthcare Conference on Wednesday, March 11, 2026. Mr. Vitalone will also participate in the BofA Securities 2026 Healthcare Conference in May 2026. McKesson Corporation has reaffirmed fiscal 2026 full year outlook as previously issued on Febru

    3/6/26 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Announces Planned CFO Transition

    Britt Vitalone announces retirement, Kenny Cheung named as successor McKesson Corporation (NYSE:MCK) today announced Britt Vitalone, Executive Vice President and Chief Financial Officer (CFO), has elected to retire after a successful and distinguished 20-year career with the company, including more than eight years as CFO. Looking ahead, Kenny Cheung will join McKesson as Executive Vice President and CFO, effective May 29, 2026. "Britt is an exceptional partner and leader. He has been instrumental in advancing the company's financial performance, engaging with shareholders, and instilling a culture of financial discipline," said Brian Tyler, Chief Executive Officer, McKesson Corporation

    3/5/26 8:10:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation Reports Fiscal 2026 Third Quarter Results and Raises Full Year Adjusted EPS Guidance

    McKesson Corporation (NYSE:MCK) has released its fiscal 2026 third quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, February 4 at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at i

    2/4/26 4:10:00 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Leadership Updates

    Live Leadership Updates

    View All

    McKesson Announces Planned CFO Transition

    Britt Vitalone announces retirement, Kenny Cheung named as successor McKesson Corporation (NYSE:MCK) today announced Britt Vitalone, Executive Vice President and Chief Financial Officer (CFO), has elected to retire after a successful and distinguished 20-year career with the company, including more than eight years as CFO. Looking ahead, Kenny Cheung will join McKesson as Executive Vice President and CFO, effective May 29, 2026. "Britt is an exceptional partner and leader. He has been instrumental in advancing the company's financial performance, engaging with shareholders, and instilling a culture of financial discipline," said Brian Tyler, Chief Executive Officer, McKesson Corporation

    3/5/26 8:10:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute's Core Ventures

    Acquisition enhances McKesson's integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures. McKesson will purchase its controlling interest for approximately $2.49 bil

    8/26/24 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of Directors

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders. "I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shar

    10/4/23 4:05:00 PM ET
    $KRMD
    $MCK
    Medical/Dental Instruments
    Health Care
    Other Pharmaceuticals

    $MCK
    Financials

    Live finance-specific insights

    View All

    McKesson Corporation Announces Fourth Quarter Fiscal 2026 Earnings Release Date and Participation in Upcoming Conferences

    McKesson Corporation (NYSE:MCK) will release its fourth quarter fiscal 2026 financial results after market close on Thursday, May 7, 2026. Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. Mr. Vitalone will be participating in Leerink Partners Global Healthcare Conference and Barclays Global Healthcare Conference on Wednesday, March 11, 2026. Mr. Vitalone will also participate in the BofA Securities 2026 Healthcare Conference in May 2026. McKesson Corporation has reaffirmed fiscal 2026 full year outlook as previously issued on Febru

    3/6/26 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation Reports Fiscal 2026 Third Quarter Results and Raises Full Year Adjusted EPS Guidance

    McKesson Corporation (NYSE:MCK) has released its fiscal 2026 third quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, February 4 at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at i

    2/4/26 4:10:00 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation Declares Quarterly Dividend

    The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on April 1, 2026, to shareholders of record on March 2, 2026. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and r

    1/28/26 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

    SC 13G/A - MCKESSON CORP (0000927653) (Subject)

    2/13/24 5:09:38 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

    SC 13G/A - MCKESSON CORP (0000927653) (Subject)

    1/25/24 1:48:52 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

    SC 13G/A - MCKESSON CORP (0000927653) (Subject)

    2/10/22 8:27:59 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care